NasdaqGS - Nasdaq Real Time Price USD

Enanta Pharmaceuticals, Inc. (ENTA)

7.21

+0.10

+(1.41%)

At close: June 5 at 4:00:01 PM EDT

7.19

-0.02

(-0.28%)

After hours: June 5 at 7:03:39 PM EDT

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 27, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 8:10 a.m. ET in New York, NY.

Business Wire 9 days ago

ENTA
+1.41%
Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

WATERTOWN, Mass., May 22, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company’s Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2025, being held May 26-30

Business Wire 14 days ago

ENTA
+1.41%
Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?

The consensus price target hints at an 189.6% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 21 days ago

ENTA
+1.41%
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Investors in Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) had a good week, as its shares rose 2.4% to close at US$5.18...

Simply Wall St. 21 days ago

ENTA
+1.41%
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -1.92% and 8.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 24 days ago

ENTA
+1.41%

PSTV
Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

WATERTOWN, Mass. AP) — Enanta Pharmaceuticals Inc. ENTA) on Monday reported a loss of $22.6 million in its fiscal second quarter.

Associated Press Finance 24 days ago

ENTA
+1.41%
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

WATERTOWN, Mass., May 12, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2025.

Business Wire 24 days ago

ENTA
+1.41%
Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates

Profound Medical (PROF) delivered earnings and revenue surprises of -24.14% and 24.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 28 days ago

ENTA
+1.41%
Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts

We recently published a list of 11 Best Breakout Stocks to Buy According to Analysts. In this article, we are going to take a look at where Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) stands against other best breakout stocks to buy according to analysts. Stock markets have been on edge in response to the US President’s aggressive […]

Insider Monkey last month

ENTA
+1.41%

^GSPC
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

WATERTOWN, Mass., April 08, 2025--Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

Business Wire last month

ENTA
+1.41%
Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

WATERTOWN, Mass., March 17, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will present at the at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 11:00 a.m. ET.

Business Wire 2 months ago

ENTA
+1.41%
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

WATERTOWN, Mass., March 12, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral presentation and three posters, including one late breaker, highlighting the company’s respiratory syncytial virus (RSV) program, will be presented at the 13th International RSV Symposium (RSV 2025) being held March 12-15 at Bourbon Cataratas do Iguazu, in Iguazu Falls,

Business Wire 2 months ago

ENTA
+1.41%
With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) insiders who purchased shares in the last 12 months were richly rewarded...

Simply Wall St. 3 months ago

ENTA
+1.41%
President of Enanta Pharmaceuticals Picks Up 5.9% More Stock

Investors who take an interest in Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) should definitely note that the...

Simply Wall St. 3 months ago

ENTA
+1.41%
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade

Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 3 months ago

ENTA
+1.41%
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 9.48% and 5.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

ENTA
+1.41%
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot

WATERTOWN, Mass. AP) — Enanta Pharmaceuticals Inc. ENTA) on Monday reported a loss of $22.3 million in its fiscal first quarter.

Associated Press Finance 3 months ago

ENTA
+1.41%
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

WATERTOWN, Mass., February 10, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended December 31, 2024.

Business Wire 3 months ago

ENTA
+1.41%
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial

The trial saw healthy volunteers infected with RSV to test the effectiveness of Shionogi’s treatment.

Clinical Trials Arena 4 months ago

ENTA
+1.41%

MRNA
Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 4 months ago

RXRX

ENTA
+1.41%

Performance Overview

Return	ENTA	S&P 500 (^GSPC)
YTD	+25.39%	+0.98%
1-Year	-41.81%	+10.93%
3-Year	-83.36%	+44.56%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Enanta Pharmaceuticals, Inc. (ENTA)

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates

Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates

Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns

President of Enanta Pharmaceuticals Picks Up 5.9% More Stock

Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial

Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?

Performance Overview